Lantern Pharma
LTRN
LTRN
27 hedge funds and large institutions have $3.93M invested in Lantern Pharma in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
39% less capital invested
Capital invested by funds: $6.5M → $3.93M (-$2.56M)
65% less call options, than puts
Call options by funds: $8K | Put options by funds: $23K
Holders
27
Holding in Top 10
–
Calls
$8K
Puts
$23K
Top Buyers
| 1 | +$85.2K | |
| 2 | +$75.7K | |
| 3 | +$26.8K | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$22.8K |
| 5 |
JP Morgan Chase
New York
|
+$41 |
Top Sellers
| 1 | -$104K | |
| 2 | -$59.7K | |
| 3 | -$30.9K | |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$6.56K |
| 5 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$6.51K |